Tin tức & Cập nhật

De-escalation of chemotherapy dose and trastuzumab duration may not increase the risk of distant relapse or death in patients with ERBB2-positive (also referred to as HER2-positive) early breast cancer and tumour infiltrating lymphocyte (TIL) levels of ≥20 percent, according to a 10-year analysis of the phase III ShortHER trial.